ArticleTranslational cancer research2026
A retrospective cohort study comparing long-term clinical outcomes between patients with and without neoadjuvant therapy in stage IB-IIB cervical cancer: a propensity score-matched study.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The management of stage IB-IIB cervical cancer (CC) remains a matter of debate. Neoadjuvant therapy (NAT) followed by surgery has emerged as a potential alternative to upfront radical surgery. This study aimed to investigate the survival outcomes of NAT followed by surgery in patients with stage IB-IIB CC, using upfront surgery alone as the comparator. Methods: CC patients who received NAT in Fujian Cancer Hospital between October 2009 and April 2013 were retrospectively enrolled. A 1:1 propensity score matching (PSM) was conducted to select a comparison cohort of surgeries without NAT from the Surveillance, Epidemiology, and End Results Program (SEER) database. Kaplan-Meier and Cox models were used to assess overall survival (OS) between the NAT and non-NAT cohorts, while recurrence-free survival (RFS) was evaluated only in the NAT cohort, as recurrence data were not available in the SEER database. Results: Following PSM, 532 matched patients per cohort (China NAT and SEER non-NAT) were analyzed with comparable baseline characteristics. The 3-year OS (90.1% Conclusions: The results indicate that NAT offers a better option in the treatment of CC patients with stage IB-IIB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.